<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

Preclinical Contract Research

Imiquimod induced Psoriasis

A validated model of psoriatic inflammation

Imiquimod (IMQ) induced Psoriasis efficacy studies

Psoriasis is a common skin disorder characterized by focal formation of inflamed, raised plaques that shed scales from excessive growth of epithelial cells and involves the following histological changes in the skin: 
  • hyperplasia of epidermal keratinocytes
  • vascular hyperplasia and ectasia
  • infiltration of T lymphocytes, neutrophils and other types of leukocytes in the affected skin. 
As experts in skin inflammation modeling, MD Biosciences is proud to present its extensive experience as one of the first laboratories to have validated the imiquimod induced psoriasis model in mice. This rapid model of psoriasis-like inflammation involves the IL-17/IL-23 axis. Imiquimod is a potent TLR7/8 ligand and potent immune modulator. Application of imiquimod on the back and ear of mice induces a psoriasis-like inflammation. 



  • Clinical Score
  • Ear Thickness
  • Biomarker analysis (protein or mRNA)
  • Cell Populations in Spleen/Lymph Node by FACS
  • Histology/IHC
  • PK blood collections

Call us today to discuss your therapeutic approach and why this model may be the right choice for your next study.



  • mouse IMQ Psoriasis 


Request Study Proposal
Imiquimod-induced psoriasis model is a TH17 driven psoriasis-like inflammation.



+41-44 986-2628
email us